Advances of ⁶⁸Ga-labelled SSR-targeted peptides (DOTA-TOC,-TATE,-NOC) PET/CT imaging and its preliminary application in neuroendocrine tumors

In recent years, ⁶⁸Ga-labelled peptides PET/CT has provided a new approach and perspective for the diagnosis of neuroendocrine tumors (NET). ⁶⁸Ge/⁶⁸Ga generator has been commercialized, with ⁶⁸Ga obtained easily. The labeling process is easy, and the ⁶⁸Ga-labelled peptides are stable.There are an increasing number of reports about the much better diagnostic performance of ⁶⁸Ga-labelled peptides PET/CT for the detection of NET lesions as compared to traditional morphological imaging procedures (CT, MRI) and somatostatin receptor scintigraphy. In addition, it can offer important clinical information in selecting treatment plan, adjusting the radiation dose and assessing the prognosis. ⁶⁸Ga-labelled peptides PET/CT is expected to be the standard method and first choice for imaging NET. An overview about the introduction and application of ⁶⁸Ga-labelled peptides PET/CT in clinical practice is presented.